



UNIVERSITÀ DEGLI STUDI GUGLIELMO MARCONI

FACOLTÀ DI SCIENZE DELLA FORMAZIONE  
CORSO DI LAUREA MAGISTRALE IN PSICOLOGIA

IL DILAGANTE SVILUPPO DELLE NUOVE SOSTANZE  
PSICOATTIVE: UN'INDAGINE ESPLORATIVA IN AREA  
STUDENTESCA NE ANALIZZA L'USO E LA CONOSCENZA IN  
GIOVANI ADOLESCENTI

Relatore:  
Chiar.<sup>mo</sup> Prof.  
Alessandro Emiliano  
Vento

Candidato:  
Marta Federici

Matr. N°: SF05079/LM51

ANNO ACCADEMICO

2018/2019

## INDICE

RINGRAZIAMENTI	4
ABBREVIAZIONI	8
INTRODUZIONE	10
CAPITOLO I: IL MERCATO ILLEGALE DELLA DROGA: IL <i>FIL ROUGE</i> DEL MONDO	12
1. Rotte e sequestri della droga in Europa	12
2. Una visione globale	18
2.1 Africa	19
2.2 Asia centrale e sud-occidentale	20
2.3 Asia orientale, sud-orientale e Oceania	20
2.4 Medio Oriente	22
2.5 Nord e centro America	22
2.6 Sud America	25
3. Italia	25
3.1 Sistema Nazionale di Allerta Precoce	27
4. Le vie della droga	28
CAPITOLO II: IL MERCATO 'LEGALE' DELLA DROGA: UNA COMPLESSA NATURA IN CRESCITA	31
1. Il <i>deepweb</i> : un mercato aperto che opera in modo nascosto	32
2. I mercati <i>darknet</i> : come funzionano?	36
2.1 Tor, 'il routing della cipolla'	44
2.2 I Bitcoin e il 'problema della doppia spesa'	45
2.3 I sistemi di reputazione: feedback, recensioni e valutazioni	47
2.4 Grams, un nuovo motore di ricerca	49
3. Il caso di Alphabay	49
CAPITOLO III: LE NUOVE SOSTANZE PSICOATTIVE	53
1. Cannabimimetici sintetici ( <i>spice drugs</i> )	54

2. Catinoni sintetici	57
2.1 Il mefedrone: la nuova droga killer	60
3. Nuovi derivati delle fenetilamine psichedeliche classiche	62
4. Oppioidi sintetici	64
5. Nuovi derivati della triptamina	66
6. Agonisti dei recettori GABA-A/GABA-B	67
6.1 I Chem-Sex Party: un fenomeno molto preoccupante	68
7. Fenciclidino-simili: Special K e Special M	71
8. Piperazine	73
9. Sostanze vegetali: Khat, Kratom e Salvia Divinorum	74
10. Prodotti farmaceutici	76
11. Performance and image enhancing drugs (PIEDs)	77
CAPITOLO IV: LEGGI E CONSUMATORI DI NPS: COSA FARE PER LIMITARE I DANNI?	79
1. Atteggiamenti, motivazioni e modelli preventivi rivolti ai consumatori di NPS	79
2. Risposte legali allo sviluppo delle NPS	83
2.1 La situazione in Italia	85
2.2 Lo Psychoactive Substances Act 2016	86
2.3 Il regolamento REACH	88
CAPITOLO V: INDAGINE IN AREA STUDENTESCA	91
1. Introduzione	91
2. Progetto	92
3. Obiettivo	93
4. Risultati	93
5. Discussione	102
CONCLUSIONI	107
BIBLIOGRAFIA	108
SITOGRAFIA	121

## **ABSTRACT**

L'elaborato ha l'obiettivo di comprendere lo sviluppo e la composizione delle Nuove Sostanze Psicoattive (NPS) che sembrano particolarmente presenti nel mercato mondiale della droga e, in alcuni casi, si presentano proprio come sostituti delle 'tradizionali' sostanze stupefacenti. Le Nuove Sostanze Psicoattive e le 'tradizionali' sostanze stupefacenti hanno in comune molti principi attivi ma, nella maggior parte dei casi, sono sostanze molto più potenti delle seconde e provocano delle conseguenze post-assunzione letali.

Si è cercato di comprendere questo 'nuovo' mondo, descrivendo il commercio mondiale, europeo e nazionale della droga, sono stati delineati i concetti di *deep web* e *darknet*, ritenute nuove ed importanti vie di commercio internazionale delle sostanze stupefacenti, descrivendo quali sono i vari tipi di NPS, il consumatore tipo e la situazione legale nazionale ed internazionale.

È stato presentato un importante studio sperimentale che ha riguardato 742 studenti, di cui 273 femmine e 469 maschi, di diversi Istituti presenti nella provincia di Viterbo, con un'età compresa tra gli 11 ed i 21 anni, ripartiti in maniera casuale tra maschi e femmine.

Obiettivo di questa ricerca è quello di andare a comprendere quali sono le abitudini di utilizzo di alcol, sigarette e sostanze stupefacenti all'interno del campione analizzato, con particolare riferimento alla conoscenza e all'uso delle Nuove Sostanze Psicoattive, ipotizzando che queste ultime possano essere presenti all'interno di un ambiente relativamente periferico, come la Provincia di Viterbo.

I risultati sono stati ottenuti tramite la somministrazione agli studenti del 'Questionario anonimo sulle conoscenze in materia di sostanze psicoattive' elaborato dall'Osservatorio sulle Dipendenze e sui disturbi psichici sotto soglia.

Osservando i vari grafici abbiamo potuto comprendere che le percentuali

di uso più alte sono relative all'alcol, che l'età più colpita in generale è quella tra 13 e 14 anni e che le sostanze psicoattive più utilizzate sono la cannabis, la cocaina, la metamfetamina, l'amfetamina, la ketamina e l'eroina.

Confrontando, infine, i risultati della ricerca presentata con quelli relativi all'ESPAD 2015, il più grande studio svolto in Europa riguardante l'uso di alcol, sigarette, droga e altre sostanze psicoattive tra giovani adolescenti, si è potuto constatare una evidente similarità tra questi due studi: in particolare è stato riscontrato che le Nuove Sostanze Psicoattive sono presenti sul territorio della provincia di Viterbo, ma in misura molto ridotta.

## **BIBLIOGRAFIA**

Advisory Council on the Misuse of Drugs ACMD (2013). Ketamine: a review of use and harm, London

AIHW Australian Institute of Health and Welfare (2017). *National Drug Strategy Household Survey, 2016*

Alatrash G., Majhail N. S. and Pile J. C., Rhabdomyolysis after ingestion of 'Foxy', a hallucinogenic tryptamine derivate. *Mayo Clinic Proceedings*, 81 (4), 550-1, 2006

Aldridge J. and Décary-Hétu D., Not an 'eBay for drugs': the cryptomarket 'Silk Road' as a paradigm shifting criminal innovation, 2014

Aldridge J. and Décary-Hétu D., Cryptomarkets and the future of illicit drug markets. *The internet and drug markets* (European Monitoring Centre for Drugs and Drug Addiction: Insights 21), Publications Office of the European Union, Luxembourg, 2016

Aranda E., Sala E., Navarro M. et al., Use of novel psychoactive substances (NPS): a description of a harm reduction center in Barcelona. *Res Adv Psychiatry* 2014, 1(Suppl. 1):36, 2014

Arlacchi P., e Lewis R., *Imprenditorialità illecita e droga. Il mercato dell'eroina a Verona*, Bologna, Il Mulino, 1990

Arunotayanun W., Dalley J. W., Huang X. P. et al., An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'novel psychoactive drugs'. *Bioorg Med Chem Lett*, 23:3411-5, 2013

Ashour A. E., Rahman A. F., and Kassem M. G., Vardenafil dihydrochloride. *Profiles Drug Subst. Excip. Relat. Methodol.*, 39:515-544, 2014

Barbagli M., Colombo A., Savon E., *Sociologia della devianza*, Il Mulino, 2003

Barker S. A., Monti J. A., Christian S. T., N.N-dimethyltryptamine: an endogenous hallucinogen. *Int Rev Neurobiol*, 22:83-110, 1981

Barratt M. J., Silk Road: eBay for drugs. *Addiction* 107, pp. 683–684, 2012

Barratt M. J., Cakic V., Lenton S., Patterns of synthetic cannabinoid use in Australia. *Drug and Alcohol Review*, 32, 141–146, 2013

Barratt M., Ferris A. and Winstock A., Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States. *Addiction* 109(5), pp. 774–783, 2014

Bergman M. K., The deep web: Surfacing hidden value. *Journal of Electronic Publishing*, 7(1), 2001

Bolding G., Hart G., Sherr L., and Elford J., Use of crystal methamphetamine among gay men in London. *Addiction*, 101(11):1622–1630, 2006

Bourne A., Reid D., Hickson F., Torres-Rueda S. and Weatherburn P., Illicit drug use in sexual settings (chemsex) and HIV/STI transmission risk behaviour among gay men in South London: findings from a qualitative study. *Sex. Transm. Infect*, 91(8):564–568, 2015

Bracchi M., Stuart D., Castles R., Khoo S., Back D. and Boffito M., Increasing use of party drugs in people living with HIV on antiretrovirals: a concern for patient safety. *AIDS*, 29(13):1585–1592, 2015

Buxton J. and Bingham T., The rise and challenge of dark net drug markets. Global Drug Policy Observatory, Swansea, 2015

Castaneto M. S., Gorelick D. A., Desrosiers N. A., Hartman R. L., Pirard S., Huestis M. A., Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. *Drug Alcohol Depend*, 144, 12–41, 2014

CCSA Canadian Centre on Substance Abuse, Deaths involving fentanyl in Canada, 2009-2014. CCENDU Bulletin, Ottawa, 2015

Celofiga A., Koprivsek J., Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: case series. *J Dual Diagn* 2014, 10:168-73, 2014

Chiappini S., Claridge H., Corkery J. et al., Special M related fatalities in the UK. *Res Adv Psychiatry*, 1(Suppl. 1):38, 2014

Choi H., Heo S., Choe S. et al., Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. *Anal Bioanal Chem* 2013, 405:3919-63, 2013

Christin N., Traveling the Silk Road: a measurement analysis of a large anonymous online marketplace. *International World Wide Web Conference Committee (IW3C2)*, Rio de Janeiro, Brazil, 2013

Collins M., Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. *Drug Testing and Analysis*, 3 (7-8), 404-16, 2011

Corazza O. and Schifano F., Ketamine-induced 'near-death experience' states in a sample of 50 misusers. *Subst Use Misuse*, 45:916-24, 2010

Corazza O., Schifano F., Simonato P. et al., Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine. *Hum Psychopharmacol*, 27:145-9, 2012

Corazza O., Simonato P., Corkery J., Trincas G., Schifano F., 'Legal highs': Safe and legal 'heavens? A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK. *Rivista di Psichiatria*, 49, 89-94, 2014

Corazza O., Valeriani G., Bersani F. S., Corkery J., Martinotti G., Bersani G. and Schifano F., 'Spice', 'kryptonite', 'black mamba': An overview of brand names and marketing strategies of novel psychoactive substances on the web. *Journal of Psychoactive Drugs*, 46(4), 287-294, 2014

Corkery J., Schifano F., Ghodse A. H., Phenazepam abuse in the UK: an emerging problem causing serious adverse health problems, including death. *Hum Psychopharmacol*, 27:254-61, 2012

Corkery J., Claridge H., Loi B. et al., Drug related deaths in the UK. *NPSAD Annual Report 2013*. London: International Centre for Drug Policy, St. George's University of London, 2014

Cox J., Reputation is everything: the role of ratings, feedback and reviews in cryptomarkets. *The internet and drug markets* (European Monitoring



Centre for Drugs and Drug Addiction: Insights 21), Publications Office of the European Union, Luxembourg, 2016

Cox J., Staying in the shadows: the use of bitcoin and encryption in cryptomarkets. *The internet and drug markets* (European Monitoring Centre for Drugs and Drug Addiction: Insights 21), Publications Office of the European Union, Luxembourg, 2016

Dargan P. I., Albert S., Wood D.M., Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change. *Oxford Journal of Medicine*, 2010, 103 (10), 875-9, 2010

Dargan P. I., Sedefov R., Gallegos A., Wood D. M., The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). *Drug Test Anal*, 3(7-8):454-63, 2011

Dargan P. I. and Wood D. M., Novel psychoactive substances: classification, pharmacology and toxicology. *Academic Press/ Elsevier*, London, 2013

DEA Drug Enforcement Administration, *Office of Diversion Control*, 'N-Benzylpiperazine. (Street Names: BZP, A2, Legal E or Legal X)', 2014

DEA Drug Enforcement Administration, *National Drug Threat Assessment Summary*. United States, 2016

Dipartimento Politiche Antidroga in collaborazione con il Sistema di Allerta Precoce New drugs, nuove sostanze psicoattive. Schede tecniche relative alle molecole registrate dal sistema nazionale di allerta precoce. *Allegato al PAN-NPS 2013*, 2013

Dipartimento Politiche Antidroga in collaborazione con il Ministero della Salute, *Update e Piano di Azione Nazionale per la prevenzione della diffusione delle Nuove Sostanze Psicoattive e dell'offerta in internet*. Roma, 2013

Dipartimento Politiche Antidroga in collaborazione con la Presidenza del Consiglio dei Ministri, *Relazione annuale al Parlamento 2017 sullo stato delle tossicodipendenze in Italia*, Roma, 2017

Dolliver D. S. and Kuhns J. B., The presence of new psychoactive substances in a Tor network marketplace environment. *Journal of Psychoactive Drugs* 48, pp. 321-329, 2016

Duxbury S. and Haynie D., The network structure of opioid distribution on a darknet cryptomarket. *Journal of Quantitative Criminology*, 2017

Ellsworth J. H., and Ellsworth M. V., *The internet business book*. Inc: John Wiley & Sons, 1994

EMCDDA and Europol, *Drugs and the darknet: Perspectives for enforcement, research and policy*. Ufficio delle pubblicazioni ufficiali dell'Unione europea, Lussemburgo, 2017

EMCDDA European Monitoring Center for Drugs and Drugs Addiction, *Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs*, Belgium, 2002

EMCDDA European Monitoring Centre for Drugs and Drug Addiction, *Risk assessment report of a new psychoactive substance: 4-methylmethcathinone (mephedrone)*, Lisbona, 2010

EMCDDA European Monitoring Centre for Drugs and Drug Addiction. *New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015)*, Publications Office of the European Union, Luxembourg, 2015

EMCDDA European Monitoring Centre for Drugs and Drug Addiction. *European Drug Report 2016: Trends and developments*. Publications Office of the European Union. Lisbon, 2016

EMCDDA European Monitoring Centre for Drugs and Drug Addiction and Eurojust. *New psychoactive substances in Europe: Legislation and prosecution – current challenges and solutions*. EMCDDA – Eurojust joint publication, Publications Office of the European Union, Luxembourg, 2016

EMCDDA European Monitoring Centre for Drugs and Drug Addiction. *Relazione europea sulla droga 2017: tendenze e sviluppi*. Ufficio delle pubblicazioni ufficiali dell'Unione europea, Lussemburgo, 2017

Emmanuel S., Onaivi. Ricerca su marijuana e cannabinoidi: metodi e protocolli. *Springer*. Pp. 128, 2006

ESPAD Report 2015. *Results from the European School Survey Project on Alcohol and Other Drugs*. The ESPAD Group.

European Commission, *Young people and drugs: Flash Eurobarometer 401*, 2014

Farrè M., Papaseit E., Pérez-Mana C. et al., Human pharmacology of mephedrone: a dose-finding pilot study. Presented at the College on Problems of Drug Dependence Meeting, San Juan, 2014

Felson M., *Crime and everyday life*, III ed., Thousand Oaks, Sage, 2002

Fisher D. G., Malow R., Rosenberg R., Reynolds G. L., Farrell N. and Jaffe A., Recreational viagra use and sexual risk among drug abusing men. *Am. J. Infect. Dis.*, 2(2):107–114, 2006

Forman R. F., Narcotics on the net: The availability of web sites selling controlled substances, *Psychiatric Services*, 57(1), 24–26, 2006

Gallimberti L., Schifano F., Forza G. et al., Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal. *Eur Arch Psychiatry Clin Neurosci*, 244:113-4, 1994

Giorgetti R., Tagliabracci A., Schifano F., Zaami S., Marinelli E. and Busardò F.P., When 'Chems' Meet Sex: Rising Phenomenon Called 'ChemSex'. *Curr Neuropharmacol*, 15(5): 762-770, 2017

Glennon R. A., Ismaiel A. E. M., Martin B., Poff D. and Sutton M., A preliminary behavioral investigation of PMMA, the 4-methoxy analog of methamphetamine. *Pharmacology Biochemistry and Behavior*, 31 (1), 9-13, 1988

Grundlingh J., Dargan P. I., El-Zanfaly M. et al., 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. *J Med*

*Toxicol*, 7:205-12, 2011

Guichhait R. B., Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland. *J Neurochem*, 26:187-90, 1976

Gustavsson D., and Escher C., Mephedrone – internet drug which seems to have come and stay. Fatal cases in Sweden have drawn attention to previously unknown substance. *Lakartidningen*, 2009, 106 (43), 2769-71, 2009

Helander A., Bäckberg M., Beck O., MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. *Clin. Toxicol. (Phila.)* 52, 901–904, 2014

Hermanns-Clausen M., Kneisel S., Szabo B. et al., Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. *Addiction* 2013, 108:534-44, 2013

Hill S. L. and Thomas S. H., Clinical toxicology of newer recreational drugs. *Journal: Clinical Toxicology*, 49(8), 705-19, 2011

Hoffman R. and Al'absi M., Khat use and neurobehavioural functions: suggestions for future studies. *Journal of Ethnopharmacology*, 2010

Hunter L. J., Dargan P. I., Benzie A., White J. A., and Wood D.M., Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. *Postgrad. Med. J*, 90(1061):133–138, 2014

Jennifer J. E. Nicol et al., Deaths from exposure to para-methoxymethamphetamine in Alberta and British Columbia, Canada: a case series. *Canadian Medical Association Journal*, 2015

Joseph J. Palamar et al., Detection of 'bath salts' and other novel psychoactive substances in hair samples of ecstasy/MDMA/"Molly" users. *Drug and Alcohol Dependence*, 2016

Karkkainen J., Raisainen M., Naukarinen H. et al., Urinary excretion of free bufotenin by psychiatric patients. *Biol Psychiatry*, 24:441-6, 1988

Kelly J. P., Cathinone derivatives: A review of their chemistry,

pharmacology and toxicology. *Drug Testing and Analysis*, 2011, 3, 439-453, 2011

King L.A., and Kicman A.T., A brief history of 'new psychoactive substances'. *Drug Testing Analysis* 3: 401-403, 2011

Kirby T., and Thornber-Dunwell M., High-risk drug practices tighten grip on London gay scene. *Lancet*, 381(9861):101-102, 2013

Lahaie E., Martinez M. and Cadet-Taïrou A., New psychoactive substances and the Internet: current situations and issues. *Tendances* 84, Observatoire Français des Drogues et des Toxicomanies (OFDT), 2013

Lewmann A., Tor and links with cryptomarkets. *The internet and drug markets* (European Monitoring Centre for Drugs and Drug Addiction: Insights 21), Publications Office of the European Union, Luxembourg, 2016

Lowry T. P., Psychosexual aspects of the volatile nitrites. *J. Psychoactive Drugs.*, 14(1-2):77-79, 1982

Luciano R. L. and Perazella M.A., Nephrotoxic effects of designer drugs: synthetic is not better!. *Nat Rev Nephrol*, 10:314-24, 2014

Markoff J., What the dormouse said: how the sixties counterculture shaped the personal computer industry. Penguin, London, 2005

Martin J., Lost on the Silk Road: Online drug distribution and the 'cryptomarket'. *Criminology and Criminal Justice*, 2013

Martin J., Drugs on the darknet: how cryptomarkets are transforming the global trade in illicit drugs. Palgrave Macmillan, Basingstoke, 2014

McCall H., Adams N., Mason D. and Willis J., What is chemsex and why does it matter? *BJM*, 351:h5790, 2015

Measham F., Moore K., Newcombe R., Welch Z., Tweaking, bombing, dabbing and stockpiling: The emergence of mephedrone and the perversity of prohibition. *Drugs and Alcohol Today*, 10, 14-21, 2010

Mechoulam R., Lander N., Breuer A. and Zahalka J., Synthesis of the individual, pharmacologically distinct, enantiomers of a

tetrahydrocannabinol derivative. *Tetrahedron: Asymmetry* 1.5 (1990): 315-18, 1990

Minervini L., Antonielli Romanini F., Solmi M. et al., Acute psychotic episode associated with the intake of a testosterone-enhancer herbal mixture purchased online. *Psychother Psychosom*, 81:248-9, 2012

Morrish P.K., Nicolaou N., Brakkenberg P., *Journal of Neurology, Neurosurgery, and Psychiatry*, 1999

Mounteney J., Oteo A., Griffiths P., *The internet and drug markets*. (EMCDDA Insights 21). Ufficio delle pubblicazioni ufficiali dell'Unione europea, Lussemburgo, 2016

Mounteney J., Oteo A. and Griffiths P., 'The internet and drug markets: shining a light on these complex and dynamic systems', *The internet and drug markets* (European Monitoring Centre for Drugs and Drug Addiction: Insights 21), Publications Office of the European Union, Luxembourg, 2016

NDEWS National Drug Early Warning System, *Southeastern Florida (Miami Area), Sentinel community Site (SCS), Drug Use Patterns and Trends, 2016*

Nelson M. E., Bryant S. M., Aks S. E., Emerging drugs of abuse. *Emerg Med Clin North Am* 2014, 32:1-28, 2014

Oluwabusi O. O., Lobach L., Akhtar U. et al., Synthetic cannabinoid-induced psychosis: two adolescent cases. *J Child Adolesc Psychopharmacol* 2012, 22:393-5, 2012

Orsolini L., Francesconi F., Papanti G. D., Giorgetti A. and Schifano F., Profiling the online recreational/prescription drugs' customers and overview of the drug vending virtual marketplaces. *Human Psychopharmacology: Clinical and Experimental*, 2015

Orsolini L., Papanti D., Corkery J., Schifano F., An insight into the deep web; why it matters for addiction psychiatry?. *Human Psychopharmacology Clinical and Experimental*, 2017

Owen G. and Savage N., Empirical analysis of Tor hidden services. *IET Information Security* 10, pp. 113-118, 2016

Palatini P., Tedeschi L., Frison G. et al., Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. *Eur J Clin Pharmacol*, 45:353-6, 1993

Papanti D., Schifano F., Botteon G. et al., 'Spiceophrenia': a systematic overview of 'Spice'-related psychopathological issues and a case report. *Hum Psychopharmacol* 2013, 28:379-89, 2013

Patton A. L., Chimalakonda K. C., Cindy L. et al., K2 toxicity: fatal case of psychiatric complications following AM2201 exposure. *J Forensic Sci*, 58:1676-80, 2013

Pearlson G. D., Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. *Jhons Hopkins medical journal*, 148,23-33, 1981

Poulsen K., Kingpin: how one hacker took over the billion-dollar cybercrime underground. Random House, New York, 2012

Rafstedt K., Hultén P., Brusiu K., Phenazepam as a drug of abuse – high frequency of prolonged symptoms. *Clin Toxicol*, 47:436-510, 2009

Romanelli F., and Smith K. M., Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. *Ann. Pharmacother*, 38(6):1024–1030, 2004

Roxburgh A., Van Buskirk J., Burns L., and Bruno R., Drugs and the internet. Issue 8, *National Drug and Alcohol Research Centre*, University of New South Wales, Sydney, 2017

Schifano F., Corkery J., Oyefeso A. et al., Trapped in the 'K-hole'; overview of deaths associated with ketamine misuse in the UK (1993-2006). *J Clin Psychopharmacol*, 28:114-6, 2008

Schifano F., Corkery J., Naidoo V. et al., Comparison between amphetamine/methylamphetamine and ecstasy (MDMA, MDEA, MDA, 4-MTA) mortality data in the UK (1997-2007). *Neuropsychobiology*, 61:122-

30, 2010

Schifano F., D'Offizi S., Piccione M. et al., Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. *Psychother Psychosom*, 80:118-22, 2011

Schifano F., Corkery J., Ghodse A. H., Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone; 'meow meow') in the UK. *J Clin Psychopharmacol* 2012, 32:710-4, 2012

Schifano F., Misuse and abuse of pregabalin and gabapentin: cause for concern?, *CNS Drugs* 2014, 28:491-6, 2014

Schifano F., Novel psychoactive substances also known as 'legal highs'. In: Davies SC (ed). *Annual report of the Chief Medical Officer 2013*, London, 2014

Schifano F., Novel psychoactive substances (NPS): clinical and pharmacological issues. *Drugs Alcohol Today*, 15(1), 1-7, 2015

Schifano F., and Orsolini L., Prescription medicines and virtual drug marketplaces; novel public health challenges. London: ACMD, 2015

Schifano F., Orsolini L., Papanti G. D., and Corkery J., Novel psychoactive substances of interest for psychiatry. *World Psychiatry*, 14(1), 15-26, 2015

Seam de Burnaga Sanchez J., Sur un homologue de l'éphedrine. *Bulletin de la Société Chimique de France*, 1929, 45, 284-86, 1929

Shanks K. G., Dahn, T., Terrell A. R., Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood case-work. *J Anal Toxicol* 2012, 36:145-52, 2012

Siddiqi S., Verney C., Dargan P., Wood D. M., Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. *Clin. Toxicol*, (Phila.) 53, 54-59, 2015

Sogawa C., Sogawa N., Tagawa J. et al., 5-methoxy-N, N-diisopro-



pyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. *Toxicol Lett*, 170:75-82, 2007

Soska K., and Christin N., Measuring the longitudinal evolution of the online anonymous marketplace ecosystem. *Proceedings of the 24th USENIX Security Symposium*. Washington DC, 2015

Soussan C., and Kjellgren A., The flip side of "spice": The adverse effects of synthetic cannabinoids as discussed on a Swedish Internet forum. *Nordic Studies on Alcohol and Drugs*, 31, 1-13, 2013

Soussan C., and Kjellgren A., Harm reduction and knowledge exchange – A qualitative analysis of drug-related Internet discussion forums. *Harm Reduction Journal*, 11, 2014

Soussan C. and Kjellgren A., The users of novel psychoactive substances: online survey about their characteristics, attitudes and motivations. *Int J Drug Policy*, 32:77-84, 2016

Smith J. B., Situation specificity of tolerance to effects of phencyclidine on responding of rats under fixed-ratio and spaced-responding schedules. *Psychopharmacology*, 103, 121-8, 1991

Spaderna M., Addy P. H., D'Souza D. C., Spicing things up: synthetic cannabinoids. *Psychopharmacology 2013*, 228:525-40, 2013

Theodore P. S., Durán R. E., and Antoni M. H., Drug use and sexual risk among gay and bisexual men who frequent party venues. *AIDS Behav*, 18(11):2178-2186, 2014

Toennes S. W., Harder S., Schramm M., Niess C., and Kauert G. F., Pharmacokinetics of cathinone, cathine and norephedrine after the chewing of khat leaves. *British Journal of Clinical Pharmacology*, vol. 56, nº 1, pp. 125-130, 2003

Tyers M. B., A classification of opiate receptors that mediate antinociception in animals, *Br J Pharmacol*, 69:503-12, 1981

Umemoto S., Nagatsuka T., Nakamura H., N-(1,2-Diphenylethyl) - piperazine derivatives. Japanese patent, Jpn Tokkyo Koho, JP 47049071

(19721209), 1972

UNODC United Nations Office on Drugs and Crime, Early warning advisory on new psychoactive substances, 2008-2016

UNODC United Nations Office on Drugs and Crime, *World Drug Report 2010*, Vienna, 2010

UNODC United Nations Office on Drugs and Crime *Global SMART Update 2013*. Vol. 9. Vienna, 2013

UNODC United Nations Office on Drugs and Crime, The Challenge of New Psychoactive Substances, *Global SMART Programme*, 2013

UNODC United Nations Office on Drugs and Crime, Responses to the annual questionnaire of Lebanon, 2015

UNODC United Nations Office on Drugs and Crime. Responses to the annual report questionnaire for Nigeria, 2015

UNODC United Nations Office on Drugs and Crime, Responses to the annual report questionnaire, 2010-2015

UNODC United Nations Office on Drugs and Crime, Annual report questionnaire for Indonesia, Japan, Republic of Korea, New Zealand, 2015

UNODC United Nations Office on Drugs and Crime, *Transnational Organized Crime in the Pacific*, 2016

UNODC United Nations Office on Drugs and Crime, *Global Synthetic Drugs Assessment*, Vienna, 2017

UNODC United Nations Office on Drugs and Crime, *The Challenge of Synthetic Drugs in East and South-East Asia: Trends and Patterns of Amphetamine-type Stimulants and New Psychoactive Substances*, 2017

UNODC United Nations Office on Drugs and Crime, *World Drug Report 2017*, Vienna, 2017

Vandrey R., Dunn K.E., Fry J. A. et al., A survey study to characterize use of Spice products (synthetic cannabinoids). *Drug Alcohol Depend* 2012, 120:238-41, 2012

Van Hout M. C. and Bingham T., 'Surfing the Silk Road': a study of users' experiences. *International Journal of Drug Policy* 24, pp. 524–529, 2013

Van Hout M. C. and Bingham T., 'Silk Road', the virtual drug marketplace: a single case study of user experiences. *International Journal of Drug Policy* 24(5), pp. 385–391, 2013

Van Hout M. C. and Brennan, R., An in-depth case examination of an exotic dancer's experience of melanotan. *Int J Drug Policy*, 25:444-50, 2014

Vardakou I., Pistos C., Spiliopoulou C., Drugs for youth via Internet and the example of mephedrone. *Toxicology Letters*, 201, 191–195, 2010

Vento, A.E. (2016). Suicidio e morte accidentale tra gli utilizzatori di NPS. *Medicina delle dipendenze – Italian Journal of the Addictions*, n.22, 2016

Vento A. E., NPS: le nuove sostanze psicoattive d'interesse per la salute pubblica, 2018

Vento A.E., Martinotti G., Cinosi E., Lupi M., Acciavatti T., Carrus D., et al., Substance use in the club scene of Rome: a pilot study. *BioMed Res Int*, 1-5., 2014

Werse B. and Morgenstern C., How to handle legal highs? Findings from a German online survey and considerations on drug policy issues, *Drug and Alcohol Today*, 12, 222–231, 2012

Winblad B., Piracetam: a review of pharmacological properties and clinical uses. *CNS Drug Rev*, 11:169-82, 2005

Winstock A. R., and Barratt, M. J., The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products, *Hum Psychopharmacol* 2013, 28:390-3, 2013

Winstock A. R., Lawn W., Deluca P., Borschmann R., Methoxetamine: An early report on the motivations for use, effect profile and prevalence of use in a UK clubbing sample. *Drug and Alcohol Review*, 2015

Woolf N., Bitcoin 'exit scam': deep-web market operators disappear with \$12m, 2015

Zawilska J. B. and Wojcieszak J., Spice/K2 drugs – more than innocent substitutes for marijuana, *Int. J. Neuropsychopharmacol*, 17, 509–525, 2014

Zawilska J. B., Andrzejczak D., Next generation of novel psychoactive substances on the horizon – A complex problem to face. *Drug and Alcohol Dependence*, 157, 1-17, 2015

## **SITOGRAFIA**

<https://www.bitcointalk.org> [ultimo accesso: 27.03.2018]

[http://www.corriere.it/salute/malattie\\_infettive/17\\_luglio\\_20/chem-sex-pur-non-rinunciare-corsa-profilassi-anti-hiv-5e194012-6d35-11e7-8b64-8c2227f4edc4.shtml](http://www.corriere.it/salute/malattie_infettive/17_luglio_20/chem-sex-pur-non-rinunciare-corsa-profilassi-anti-hiv-5e194012-6d35-11e7-8b64-8c2227f4edc4.shtml) [ultimo accesso: 29.04.2018]

<https://www.criptoalutonline.com/2017/10/28/deep-web-e-le-criptoalute/> [ultimo accesso: 27.03.2018]

[http://d.repubblica.it/benessere/2013/06/28/news/droghe\\_sintetiche\\_ad\\_olescenza-1687408/](http://d.repubblica.it/benessere/2013/06/28/news/droghe_sintetiche_ad_olescenza-1687408/) [ultimo accesso: 22.04.2018]

<https://www.danno.ch/sostanze/nuove-sostanze-psicoattive-nsp> [ultimo accesso: 12.06.2018]

<https://www.drugs-forum.com> [ultimo accesso 25.02.2017]

<https://www.echa.europa.eu/it/regulations/clp/understanding-clp> [ultimo accesso: 29.05.2018]

<https://www.echa.europa.eu/it/regulations/reach/understanding-reach> [ultimo accesso: 28.05.2018]

<http://www.emcdda.europa.eu/about> [ultimo accesso: 05.03.2018]

<http://www.emcdda.europa.eu/publications/joint-reports/MT-45> [ultimo accesso 23.04.2018]

<http://www.emcdda.europa.eu/attachements.cfm/att.242501.EN.TDAS15001ENN.pdf> [ultimo accesso: 21.04.2018].

[http://www.emcdda.europa.eu/attachements.cfm/att.222584\\_EN.AH-7921.pdf](http://www.emcdda.europa.eu/attachements.cfm/att.222584_EN.AH-7921.pdf) [ultimo accesso 23.04.2018].

<https://www.erowid.org> [ultimo accesso: 25.04.2018]

<https://www.eticaeconomia.it/una-descrizione-quasi-informatica-del-funzionamento-di-bitcoin/> [ultimo accesso 04.04.2018]

<http://www.europol.europa.eu/about-europol/our-thinking> [ultimo accesso: 05.03.2018]

<https://www.gov.uk/government/collections/psychoactive-substances-bill-2015> [ultimo accesso: 27.05.2018]

<http://www.informazionisuifarmaci.it/il-ritorno-degli-zombie-le-nuove-sostanze-psychoattive-nps> [ultimo accesso: 09.06.2018]

<http://www.justice.gov/usao/nys/pressreleases/November14/DarkMarketTakedown.php> [ultimo accesso 03.04.2018]

<http://www.know-drugs.ch/2012/i/info-sostanze/ghb-gbl.htm> [ultimo accesso: 24.04.2018]

<http://www.politicheantidroga.gov.it/it/dipartimento/competenze> [ultimo accesso: 05.03.2018]

<http://www.psiconautica.in/index.php/psiconautica/16-stati-altri/614-psiconauta> [ultimo accesso: 26.03.2018]

<http://www.reach.gov.it/reach-sintesi> [ultimo accesso: 28.05.18]

<http://www.reach.sviluppoeconomico.gov.it/reach-in-breve> [ultimo accesso: 28.05.2018]

[http://www.salute.gov.it/portale/temi/p2\\_6.jsp?id=3729&area=sostanzeStupefacenti&menu=vuoto](http://www.salute.gov.it/portale/temi/p2_6.jsp?id=3729&area=sostanzeStupefacenti&menu=vuoto) [ultimo accesso: 30.05.2018]

<http://www.sdf.org.uk/wp-content/uploads/2017/11/Psychoactive-Substances-Act-2016.pdf> [ultimo accesso: 27.05.2018]

<http://www.sipad.network/droga-bilancio-del-2017/> [ultimo accesso: 05.03.2018]

<http://www.theonionrouter.com/> [ultimo accesso: 04.04.2018]

<http://www.theguardian.com/technology/2015/mar/18/bitcoin-deep-web-evolution-exit-scam-12-million-dollars> [ultimo accesso: 03.04.2018]

<http://www.treccani.it/enciclopedia/web-2-0/> [ultimo accesso: 05.03.2018]

[http://www.treccani.it/enciclopedia/netnografia\\_%28Lessico-del-XXI-Secolo%29/](http://www.treccani.it/enciclopedia/netnografia_%28Lessico-del-XXI-Secolo%29/) [ultimo accesso: 25.03.2018]

<https://www.unodc.org/LSS/SubstanceGroup/Details/275dd468-75a3-4609-9e96-cc5a2f0da467> [ultimo accesso: 22.04.2018]

<https://www.unodc.org/LSS/Page/NPS> [ultimo accesso: 20.04.2018]

<https://www.unodc.org/LSS/SubstanceGroup/Details/ae45ce06-6d33-4f5f-916a-e873f07bde02> [ultimo accesso: 20.04.2018]

<https://www.unodc.org/LSS/SubstanceGroup/Details/8242b801-355c-4454-9fdc-ba4b7e7689d5> [ultimo accesso: 25.04.2018]

<https://www.unodc.org/LSS/SubstanceGroup/Details/67b1ba69-1253-4ae9-bd93-fed1ae8e6802> [ultimo accesso: 21.04.2018]

<https://www.vanityfair.it/news/approfondimenti/2018/01/19/la-droga-dello-stupro-ecco-che-cose> [ultimo accesso: 24.04.2018]